Canadian Solar beat on the top and bottom lines yesterday, but its stock barely budged. Now that the stock market sell-off is ...
NRx has refiled its Abbreviated New Drug Application for KETAFREE™ (preservative free ketamine), received supportive ...
CEO Capone announced, "we are reducing our revenue guidance from $21.5 million to $18.5 million," citing decreased BARDA ...
Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback